With its innovative Clinical Trials Network, influential annual meeting and high-impact journals, SNMMI encourages and facilitates research and science for the nuclear medicine and molecular imaging field. Learn more.

Clinical Trials Network

The Clinical Trials Network (CTN) provides tools and resources to promote faster, more cost-effective drug development and increase the availability and performance of molecular imaging radiopharmaceuticals for use in the clinic. Our Mission is to advance the use of molecular imaging agents in clinical trials through standardization of chemistry and imaging methodology. This includes using imaging radiopharmaceuticals during the course of drug development, as well as bringing new radiopharmaceuticals to regulatory approval. Programs developed over the past 5 years include a comprehensive registry of qualified imaging sites and radiopharmaceutical manufacturers, a robust scanner validation program, access to standardized imaging protocols and a very strong clinical research education curriculum.


  • April 7, 2017PET Radiotracer Design for Monitoring Targeted Immunotherapy
    In an article published in the April issue of “The Journal of Nuclear Medicine,” researchers at Stanford University in California provide a template for assessing new positron emission tomography (PET) radiotracers that can accurately identify molecules in cancer cells that prevent the immune system from attacking the cancer.
  • April 6, 2017Reduced FDG dose levels for PET/MRI show mixed results
    Even though a lower dose of FDG had no significantly adverse effect on lesion detection for most adult cancer patients undergoing a whole-body PET/MRI scan, German researchers recommend that clinicians stay with recommended levels to avoid artifacts, according to a study published online March 30 in "The Journal of Nuclear Medicine."
  • April 4, 2017PET identifies cell mutations in NSCLC patients
    With the help of FDG-PET and an advanced image analysis technique known as radiomics, researchers have identified genetic cell mutations that can cause non-small cell lung cancer (NSCLC), according to a study published in the April issue of "The Journal of Nuclear Medicine."
  • April 1, 2017Advanced FDG-PET Image Analysis Identifies Cell Mutations in Cancer Patients
    Researchers have used positron emission tomography (PET) to successfully identify genetic cell mutations that can cause lung cancer. The research, published in the featured article of the April 2017 issue of “The Journal of Nuclear Medicine,” shows that an advanced image analysis technique, radiomics, can non-invasively identify underlying cell mutations in patients with non-small cell lung cancer (NSCLC).
  • March 8, 2017F-18-fluciclovine PET/CT better targets radiotherapy for recurrent prostate cancer
    CT, MR and nuclear medicine bone scans are conventionally used to guide and monitor targeted treatment for recurrent prostate cancer, but researchers at the Winship Cancer Institute of Emory University may have found a better alternative. Preliminary results in a three-year study that found fluorine-18-fluciclovine PET/CT can improve radiotherapy targeting were published in the March issue of "The Journal of Nuclear Medicine."
  • March 6, 2017Fluciclovine PET/CT Improves Radiotherapy Targeting for Recurrent Prostate Cancer
    The featured clinical investigation article of the March 2017 issue of "The Journal of Nuclear Medicine" demonstrates that the PET radiotracer fluciclovine (fluorine-18; F-18) can help guide and monitor targeted treatment for recurrent prostate cancer, allowing for individualized, targeted therapy.
  • March 2, 2017New PET tracer shows promise for atherosclerosis
    European researchers have developed a PET tracer that has shown the ability to quickly and noninvasively identify life-threatening atherosclerotic plaques, according to a study published in the March issue of "The Journal of Nuclear Medicine."
  • March 1, 2017New PET Radiotracer Identifies Inflammation in Life-Threatening Atherosclerosis
    In the featured article of the March 2017 issue of "The Journal of Nuclear Medicine," researchers demonstrate that a new positron emission tomography (PET) radiotracer, gallium-68 (Ga-68)-pentixafor, can quickly and non-invasively identify life-threatening atherosclerotic plaques. The tracer binds to the CXCR4 receptor on inflammatory cells present in atherosclerotic plaques—making it possible to find and treat atherosclerosis early.

Preclinical Imaging

CMIIT’s mission is to engage the molecular imaging community and leverage the SNMMI infrastructure to advance the adoption of emerging molecular imaging technologies and probes in preclinical and clinical applications. One of the goals is to develop educational resources for a “translational researcher”. CMIIT will provide researchers with needed education and training on the “nuts and bolts” of translating and transitioning an agent or technique from pre-clinical research into the clinical practice such as tracer development, equipment, and funding.

The Nuclear Medicine Clinical Trial Group, LLC

Under the auspices of the Society of Nuclear Medicine and Molecular Imaging, the Nuclear Medicine Clinical Trial Group(NMCTG) assists industry partners and academic investigators in managing clinical research activities.  Its goals include ensuring quality imaging is conducted in drug or diagnostic clinical trials and providing training for molecular imaging professionals performing clinical research. Many of the programs established under the Clinical Trials Network, such as its robust Education Program, provide support to the NMCTG to help carry out its mission.